FLWPF (The Flowr) Debt-to-Equity: -2.92 (As of Sep. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is The Flowr Debt-to-Equity?

The Flowr FLWPF -90.00% Debt-to-Equity is -2.92 as of Sep. 2022.

The Flowr's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $0.44 Mil. The Flowr's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2022 was $6.77 Mil. The Flowr's Total Stockholders Equity for the quarter that ended in Sep. 2022 was $-2.47 Mil. The Flowr's debt to equity for the quarter that ended in Sep. 2022 was -2.92.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for The Flowr's Debt-to-Equity or its related term are showing as below:

FLWPF's Debt-to-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.27
* Ranked among companies with meaningful Debt-to-Equity only.

The Flowr  (OTCPK:FLWPF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

The Flowr Debt-to-Equity Related Terms

The Flowr Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for The Flowr's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The Flowr Debt-to-Equity Chart

The Flowr Annual Data
Trend Jun17 Jun18 Dec19 Dec20 Dec21
Debt-to-Equity
0.00 0.00 0.38 0.55 1.23

The Flowr Quarterly Data
Sep17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.43 1.23 1.27 -63.08 -2.92

FLWPF vs ZTS, CTLT, VTRS: Debt-to-Equity Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, The Flowr's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

The Flowr Debt-to-Equity vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, The Flowr's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where The Flowr's Debt-to-Equity falls into.


The Flowr Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

The Flowr's Debt to Equity Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(19.211 + 7.144) / 21.393
=1.23

The Flowr's Debt to Equity Ratio for the quarter that ended in Sep. 2022 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.442 + 6.766) / -2.471
=-2.92

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of -2.92 mean?
The Flowr (FLWPF) has a Debt-to-Equity of -2.92 as of Sep. 2022. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on The Flowr and its competitors.
Is The Flowr's Debt-to-Equity too high?
The Flowr's current Debt-to-Equity is -2.92.
How does The Flowr's Debt-to-Equity compare to ZTS and CTLT?
The Flowr's Debt-to-Equity of -2.92 can be compared against companies in the Drug Manufacturers industry. The industry median Debt-to-Equity is 0.27. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 812 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on The Flowr and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. The Flowr's current Debt-to-Equity is -2.92. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is The Flowr stock overvalued right now?
The Flowr (FLWPF) has a current Debt-to-Equity of -2.92. The current Debt-to-Equity is -2.92. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For The Flowr (FLWPF), the current Debt-to-Equity is -2.92 as of Sep. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

The Flowr Business Description

Address 365 Bay Street, Suite 800, Toronto, ON, CAN, M5H 2V1
The Flowr Corp is a Toronto-headquartered cannabis company with operations in Canada and Europe. Its Canadian operating campus, located in Kelowna, BC, includes a purpose-built, GMP-designed indoor cultivation facility; an outdoor and greenhouse cultivation site; and a R&D facility that is awaiting licensing from Health Canada. From this campus, Flowr produces recreational and medicinal products. Internationally, it intends to service the global medical cannabis market through its subsidiary Holigen, which has a license for cannabis cultivation in Portugal and operates GMP licensed facilities in Portugal.